Solid Tumor Clinical Trial
Official title:
Phase I Study to Evaluate the Maximum Tolerated Dose of the Combination of SH003 and Docetaxel in Patients With Solid Cancer
The study is designed as a single Group, Dose Elevating trial which evaluates safety to
confirm the final maximum tolerated dose by the combination of oral administration of SH003
to docetaxel administered patients.
Firstly, 3 subjects is recruited and administered for 21 days for the starting dose of 2,400
mg / day. If no DLT occurs, raise the dose to a secondary dose of 3,600 mg / day. If DLT
occurs, additional 3 subjects are recruited and administered for 2,400mg / day. After, If two
or more of the six subjects shows DLT, stop the capacity increase, whereas if DLT occurs in
less than 1 person, increase the dose to 3,600 mg / day. Next, 3 subjects is recruited and
administered for 21 days for a dose of 3,600 mg / day. If no DLT occurs, raise the dose to
4,800 mg / day. If DLT occurs, 3 subjects are additionally recruited and administered for
3,600 mg / day. After, If two or more of the six subjects shows DLT, stop the capacity
increase, whereas if DLT occurs in less than 1 person, increase the dose to 4,800 mg / day.
Finally, 3 subjects is recruited and administered for a dose of 4,800 mg / day. If no DLT
occurs, complete the study. If DLT occurs, additional 3 subjects are recruited and
administered for 4,800mg / day and complete the study after observation.
Status | Not yet recruiting |
Enrollment | 9 |
Est. completion date | August 2021 |
Est. primary completion date | May 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients aged above 19 years 2. Patients with histologically or cytologically confirmed lung cancer or breast cancer for which standard curative measures do not exist or are no longer effective 3. Patients who have not received chemotherapy, radiotherapy or surgery within the last 4 weeks and no residual toxicity associated with the previous treatment (Grade 1 or higher adverse event according to Common Terminology Criteria for Adverse Events (CTCAE) ver 5.0 from the National Cancer Institute (NCI) 4. ECOG Performance Status = 2 5. Life expectancy estimated to be at least 12 weeks 6. Patients with the ability to swallow tablets 7. Patients with measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 8. Patients with proper organ function as follows i. Bone marrow function: haemoglobin =8 g/dL, absolute neutrophil count =1,500/uL, and platelets = 100,000/uL ii. Liver function: total bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) = 2.5 times the upper limit of normal (ULN) (if patients with liver metastasis, = 5 times the ULN) iii. Renal function: Serum creatinine = 1.5 times the ULN or creatinine clearance according to the Cockroft-Gault equation = 60 ml/min 9. No possibility of pregnancy if the participant is female (over 60 years of age, without menstruation for more than one year, or underwent hysterectomy or bilateral oophorectomy). If there is a possibility of pregnancy, pregnancy test should be conducted prior to participation in the study to prove that it is not pregnancy 10. Patients who agree to use effective means of contraception during the trial and up to 8 weeks after final administration 11. Patients with the ability to understand the study and who are willing to sign a written informed consent document Exclusion Criteria: 1. Patients undergoing any systemic therapy or regional therapy including radiotherapy, for the purpose of treating cancer 2. Participants with known hypersensitivity to any study drug component, including Astragalus membranaceus, Angelica gigas, Trichosanthes Kirilowii Maximowicz, and polysorbate 80 3. Patients with active infections requiring treatment (active hepatitis A, B, and C viruses, human immunodeficiency virus, tuberculosis) 4. Patients with history of human immunodeficiency virus infection 5. Patients with uncontrolled cardiovascular diseases (unstable angina, heart failure, myocardial infarction, hypertension that remains uncontrolled: 140/90 mm Hg or higher) 6. Patients with active cytomegalovirus infection within the past 4 weeks 7. Patients who have experienced major surgery on cerebrovascular disease such as acute coronary syndrome, stroke, etc., within the past year 8. pregnant or lactating females 9. Patient with metastatic encephalopathy with symptoms 10. Patients who have donated blood or participated in other clinical trials of medicine or medical devices within the past month 11. Patient underwent organ transplantation including allogenic stem cell transplantation 12. Patients with complications of infectious diseases 13. Patients with suspected fever caused by infection 14. Patients with substance abuse or any neurological, medical, psychological, or sociological conditions that could potentially interfere with their compliance to the study protocol or interpretation of study results 15. Patients who are judged inappropriate for the study by investigator 16. Patients who are judged to have lost their ability to consent due to accompanying disease such as dementia |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kyunghee University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity | adverse event according to CTCAE | up to 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |